novo direct semaglutide Nordisk gets into the direct-to-patient game with Wegovy Novo Nordisk's Wegovy pill to

The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons

Conversely, younger patients with POP present distinct expression profiles, with endothelial cells, fibroblasts, and macrophages highly expressing COL3A1, MMP11, and S100A8, indicating an enrichment of genes associated with ECM metabolism (Li et al

Wegovy is licensed for chronic weight management in adults with obesity or overweight with comorbidities

Sofwave does this really well, as do Ulthera, Thermage, ThermiTight, and PrecisionTX